Multivariate analysis of progression-free survival
| Effect . | P value . | Hazard ratio . | 95% confidence interval . |
|---|---|---|---|
| PFS | |||
| Developed CRS | .239 | 0.79 | 0.53-1.17 |
| Peak ferritin >5000 | <.001 | 2.61 | 1.71-3.98 |
| LDH>ULN | <.001 | 2.11 | 1.49-2.98 |
| Stage 3-4 | .333 | 1.21 | 0.82-1.80 |
| Bulky disease | .219 | 1.27 | 0.87-1.87 |
| Refractory to most recent chemo vs primary refractory | .427 | 0.86 | 0.60-1.24 |
| Relapsed vs primary refractory | .085 | 0.70 | 0.47-1.05 |
| Received steroids | .740 | 0.73 | 0.52-1.03 |
| Bridging therapy | .011 | 1.58 | 1.11-2.24 |
| Effect . | P value . | Hazard ratio . | 95% confidence interval . |
|---|---|---|---|
| PFS | |||
| Developed CRS | .239 | 0.79 | 0.53-1.17 |
| Peak ferritin >5000 | <.001 | 2.61 | 1.71-3.98 |
| LDH>ULN | <.001 | 2.11 | 1.49-2.98 |
| Stage 3-4 | .333 | 1.21 | 0.82-1.80 |
| Bulky disease | .219 | 1.27 | 0.87-1.87 |
| Refractory to most recent chemo vs primary refractory | .427 | 0.86 | 0.60-1.24 |
| Relapsed vs primary refractory | .085 | 0.70 | 0.47-1.05 |
| Received steroids | .740 | 0.73 | 0.52-1.03 |
| Bridging therapy | .011 | 1.58 | 1.11-2.24 |
Boldfaced values indicate factors that had a statistically significant impact on multivariate analysis.